http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오늘 본 자료
Optimization Layout of Anhui Provincial Construction Engineering Quality Inspection Institutions
Yingrui Wang,Heping Pan,Minhong Ye 보안공학연구지원센터 2016 International Journal of Smart Home Vol.10 No.3
Construction engineering quality inspection is an important means to ensure the quality and safe use of construction engineering. On the base of analyzing the status and the main problems of Anhui provincial construction engineering quality inspection institutions, the five principles were proposed to put forward the total control, optimize the structure and increase and development ability, moderate competition and standard development. By optimizing the detection mechanism, enhancing the overall level of the testing agencies, and strengthening supervision, to achieve a basic balance and reasonable layout of supply and demand in various cities and regions. It provides reference for the research and practice of the supervision and management of construction engineering quality test institutions.
Weiguang Gu,Hua Zhang,Yiyu Lu,Minjing Li,Shuang Yang,Jianmiao Liang,Zhijian Ye,Zhihua Li,Minhong He,Xiaoliang Shi,Fei Wang,Dong You,Weiquan Gu,Weineng Feng 대한암학회 2023 Cancer Research and Treatment Vol.55 No.3
Purpose We aimed to evaluate whether the addition of pemetrexed is effective in improving progression-free survival (PFS) in epidermal growth factor receptor (EGFR)–mutated patients with or without concomitant alterations. Materials and Methods This multicenter clinical trial was conducted in China from June 15, 2018, to May 31, 2019. A total of 92 non–small cell lung cancer (NSCLC) patients harboring EGFR-sensitive mutations were included and divided into concomitant and non-concomitant groups. Patients in each group were randomly treated with EGFR–tyrosine kinase inhibitor (TKI) monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1. PFS was recorded as the primary endpoint. Results The overall median PFS of this cohort was 10.1 months. There were no significant differences in PFS between patients with and without concomitant and between patients received TKI monotherapy and TKI combined with pemetrexed (p=0.210 and p=0.085, respectively). Stratification analysis indicated that patients received TKI monotherapy had a significantly longer PFS in non-concomitant group than that in concomitant group (p=0.002). In concomitant group, patients received TKI combined with pemetrexed had a significantly longer PFS than patients received TKI monotherapy (p=0.013). Molecular dynamic analysis showed rapidly emerging EGFR T790M in patients received TKI monotherapy. EGFR mutation abundance decreased in patients received TKI combined chemotherapy, which supports better efficacy for a TKI combined chemotherapy as compared to TKI monotherapy. A good correlation between therapeutic efficacy and a change in circulating tumor DNA (ctDNA) status was found in 66% of patients, supporting the guiding role of ctDNA minimal residual disease (MRD) in NSCLC treatment. Conclusion EGFR-TKI monotherapy is applicable to EGFR-sensitive patients without concomitant alterations, while a TKI combined chemotherapy is applicable to EGFR-sensitive patients with concomitant alterations. CtDNA MRD may be a potential biomarker for predicting therapeutic efficacy.